TY - JOUR AU - Tsai, Richard AU - Hervey, John AU - Hoffman, Kathleen AU - Wood, Jessica AU - Johnson, Jennifer AU - Deighton, Dana AU - Clermont, Donald AU - low, Brian AU - Goldberg, Stuart L PY - 2022 DA - 2022/1/5 TI - COVID-19疫苗在癌症、自身免疫性疾病或其他严重共病患者中的犹豫和接受:横截面,基于互联网的调查乔- JMIR公共卫生Surveill SP - e29872六世- 8 - 1千瓦COVID-19 KW -疫苗KW -犹豫KW -癌症KW -自身免疫性疾病KW -疫苗接种KW -并发症KW - SARS-CoV-2 KW -调查KW -横断面KW -发病率KW -安全KW -脆弱KW -感知KW -态度AB -背景:个人患有条件已经被COVID-19不成比例的影响。由于COVID-19疫苗的监管试验排除了免疫功能低下的患者，因此很少有癌症和自身免疫性疾病患者入组。由于现有的疫苗安全性数据有限，脆弱人群对疫苗的态度可能存在矛盾。目的:评估严重合并症患者COVID-19疫苗犹豫和接受的流行率和独立预测因素，并评估已接种疫苗者自我报告的副作用。方法:我们于2021年1月15日至2021年2月22日在Inspire(一个拥有220多万合并症患者的在线健康社区)的随机样本中进行了一项55项的横断面在线调查。采用多变量回归分析确定与疫苗犹豫和接受相关的独立因素。结果:在被邀请参与Inspire健康社区的996,500名成员中，收到了21,943人(2.2%)的回复。受访者居住在123个国家(美国:16,277/21,943,74.2%)，年龄中位数在56-65岁之间，受过高等教育(大学或研究生学位:10,198/17,298,58.9%)，并具有不同的政治倾向。所有受访者自我报告至少有一种合并症:癌症，27.3% (5459/ 19980); autoimmune diseases, 23.2% (4946/21,294); chronic lung diseases: 35.4% (7544/21,294). COVID-19 vaccine hesitancy was identified in 18.6% (3960/21,294), with 10.3% (2190/21,294) declaring that they would not, 3.5% (742/21,294) stating that they probably would not, and 4.8% (1028/21,294) not sure whether they would agree to be vaccinated. Hesitancy was expressed by the following patients: cancer, 13.4% (731/5459); autoimmune diseases, 19.4% (962/4947); chronic lung diseases: 17.8% (1344/7544). Positive predictors of vaccine acceptance included routine influenza vaccination (odds ratio [OR] 1.53), trust in responsible vaccine development (OR 14.04), residing in the United States (OR 1.31), and never smoked (OR 1.06). Hesitancy increased with a history of prior COVID-19 (OR 0.86), conservative political leaning (OR 0.93), younger age (OR 0.83), and lower education level (OR 0.90). One-quarter (5501/21,294, 25.8%) had received at least one COVID-19 vaccine injection, and 6.5% (1390/21,294) completed a 2-dose series. Following the first injection, 69.0% (3796/5501) self-reported local reactions, and 40.0% (2200/5501) self-reported systemic reactions, which increased following the second injection to 77.0% (1070/1390) and 67.0% (931/1390), respectively. Conclusions: In this survey of individuals with serious comorbid conditions, significant vaccine hesitancy remained. Assumptions that the most vulnerable would automatically accept COVID-19 vaccination are erroneous and thus call for health care team members to initiate discussions focusing on the impact of the vaccine on an individual’s underlying condition. Early self-reported side effect experiences among those who had already been vaccinated, as expressed by our population, should be reassuring and might be utilized to alleviate vaccine fears. Health care–related social media forums that rapidly disseminate accurate information about the COVID-19 vaccine may play an important role. SN - 2369-2960 UR - https://publichealth.www.mybigtv.com/2022/1/e29872 UR - https://doi.org/10.2196/29872 UR - http://www.ncbi.nlm.nih.gov/pubmed/34709184 DO - 10.2196/29872 ID - info:doi/10.2196/29872 ER -